Navigation Links
OncoGenex Pharmaceuticals Files Shelf Registration Statement
Date:6/26/2009

BOTHELL, WA and VANCOUVER, June 26 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has filed a shelf registration statement on Form S-3 with the US Securities and Exchange Commission and an MJDS prospectus under the multi-jurisdictional disclosure system in the Province of British Columbia.

"It is prudent for us to re-establish a three-year shelf registration statement to provide us with the flexibility to support future opportunities," said Scott Cormack, President and CEO of OncoGenex. "Our focus remains on securing a development and commercialization partner for our OGX-011 program. Based on our discussions with potential partners to date, we believe that a partner would fund most or all of the development costs for our OGX-011 program. Accordingly, we do not expect to offer at the present time securities under this shelf registration to fund our Phase 3 clinical trials for OGX-011."

OncoGenex elected to terminate its previous shelf registration statement originally filed in July 2007.

If declared effective by the SEC and the British Columbia Securities Commission, the shelf registration statement and MJDS prospectus, respectively, will permit OncoGenex Pharmaceuticals to sell, from time to time over a three year period in one or more public offerings, shares of its common stock, shares of its preferred stock, warrants to purchase its common stock or preferred stock or debt securities, or any combination of such securities, for proceeds in the aggregate amount of up to $100 million. The terms of any such future offerings, if any, and the type of equity or debt securities would be established at the time of the offering.

A shelf registration statement relating to these securities has been filed with the SEC and an MJDS prospectus has been filed with the British Columbia Securities Com
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
3. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
4. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
5. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
6. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
7. OncoGenex Reports First Quarter Financial Results
8. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
9. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
10. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
11. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...I, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (N...gy, and medical-device research and,development ou... United States,announced that it had been selecte...st for the fifth consecutive year. The list recogn...echnology, media, and telecommunications,industrie...
(Date:11/29/2009)... in German . , The concept of confinement i...most famous example is that of quarks which bind t...lla Lake from Helmholtz-Zentrum Berlin together wi...the first time an experimental realization and a p...nsed matter system. , The concept of confinement...
(Date:11/27/2009)...ber 27 Stallergenes has ...) in both adults and children,through a Mutual Rec...re,Oralair(R) has been marketed, was the reference...ered in Austria, Belgium, Bulgaria, Cyprus, the,Cz...ngary, Ireland, Italy,Latvia, Lithuania, Luxembou...
(Date:11/25/2009)...C., Nov. 25 Research Triangle Park...ient, single-treatment water purification system N...hra Pradesh, Minister of Rural Water Supply, Hon. ...India today. Initial tests, performed at Indian In... the majority of the drinking water available in I...
Breaking Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Spinons -- confined like quarks 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 2STALLERGENES is Granted a Marketing Authorization for Oralair(R) in Europe 3North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2
... Feb. 25 The International,Confocal Microscopy Wo...ssionals and students, has been formed as a means ...lective confocal microscopy (RCM) in,patient care....bers worldwide.,Dermatologists, dermascopists, der...ssionals interested in learning more about RCM sho...
...25 Barr Pharmaceuticals,Inc. (NYSE: BRL ) today ...cals, Inc., has received notification that the U.S...for review its New Drug Application,(NDA) for Lo S...lets 0.10,mg/0.02 mg and ethinyl estradiol tablets...ompany is seeking approval to manufacture and mark...
.... 25 Nile Therapeutics,Inc. (OTC Bulletin Board: ...eveloping therapies for cardiovascular disease, is...Lieu, M.D., F.A.C.C. as its Vice President of,Clin...eu to Nile. Dr. Lieu has extensive,cardiovascular ...mmediately,beneficial to Nile and our CD-NP and 2N...
Other Biology Technology:International Confocal Microscopy Working Group Established to Advance Practice of Reflective Confocal Microscopy 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 2Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 3Duramed's Lo SEASONIQUE(R) NDA Accepted for Filing by FDA 4Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 2Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics 3
(Date:11/26/2009)... MRSA (methicillin-resistant Staphylococcus Aure...annihilation as low-temperature plasma prototype d...asy and unfailing bactericidal cocktails. , Two ...icient disinfection of healthy skin (e.g. hands an...ria can pose a lethal threat; and another to shoot...
(Date:11/25/2009)... Athens, Ga. Bacteria don,t have easy lives. In ...the bugs, they have natural enemies called bacteri...rth every two days. , Still, bacteria and anoth...iscovered in extreme environments such as deep-sea...art because they have a built-in defense system th...
(Date:11/25/2009)... MADISON, WI, NOVEMBER 25, 2009 Soil is the linc...re, and hydrosphere meet. Despite that, many stude...s, but nothing more. Soil science educators are ch... public recognize the critical importance of soil ...y soil science and earth science teachers at Unive...
Breaking Biology News(10 mins):Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3It's not just dirt! 2Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009 13954 1Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009 13954 2Scientists Find Clue to Dangerous Side Effect of MS Drug 56673 1Scientists Find Clue to Dangerous Side Effect of MS Drug 56673 2Scientists Find Clue to Dangerous Side Effect of MS Drug 56673 3Kmart Pharmacy Flu Clinics Begin September 10 2009 56669 1Kmart Pharmacy Flu Clinics Begin September 10 2009 56669 2Kmart Pharmacy Flu Clinics Begin September 10 2009 56669 3
...oking for a mate who in everyday conversation can ... a musician, Northwestern University researchers s...opean Journal of Neuroscience , an interdisciplina...rovides biological evidence that musical training ...ion in sound. , "Quickly and accurately identify...
... Park Zoo post-doctoral researcher Carson Murray, ...s from one of the world,s foremost medical researc...and her mentors, Elizabeth Lonsdorf, Ph.D. and Rac...a McClintock, Ph.D. of the University of Chicago w...panzees and discover how stress relates to materna...
...ch 3, 2009) When it comes to solving complex prob...and biomedical engineer, looks to nature for solut...n has produced, von Maltzahn is currently helping ...roving tumor detection and therapeutic delivery in...ts. , Today, the 28-year-old Ph.D. candidate in ...
Other Biology News:Musicians have biological advantage in identifying emotion in sound 2Musicians have biological advantage in identifying emotion in sound 3Lincoln Park Zoo scientists awarded National Institutes of Health grant 2MIT student develops new innovations to selectively kill cancer cells 2MIT student develops new innovations to selectively kill cancer cells 3MIT student develops new innovations to selectively kill cancer cells 4
Frozen Tissue Section Panel - Monkey (Cynomolgus) Normal Tissue, Multi-tissue I from BioChain
XRS Series Precision Linear Tables from Parker Hannifin Corporation
Goat Anti-UGT1A6 (D-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
... features T Squareds patented high efficiency dyna...ce and efficiency. With the most compact, lightwei...al for use in portable air and gas applications.,...fficiency. , Includes DC Motor. , Provides quiet ...
Biology Products: